Rajen Mody Advances in Neuroblastoma Research Congress 2016

Abstracts this author is presenting:

• Phase II randomized trial of irinotecan/temozolomide (I/T) with temsirolimus (TEM) or dinutuximab plus granulocyte colony stimulating factor (DIN/GMCSF) in children with refractory or relapsed neuroblastoma: a report from the Children’s Oncology Group (COG) — Plenary Session 4